GlyCLICK®: From Kit to Clinic
GenovisWebinar, Video
Discover the benefits and potential of using GlyCLICK®, a site-specific conjugation technology platform, for generating ADCs applicable from early-stage R&D through to clinical manufacture.
GlyCLICK is a three-step conjugation technology for site-specific and quantitative conjugation of IgG. Specific Fc N-glycan hydrolysis allows for site-specific conjugation at the core GlcNAcs followed by robust click-chemistry and results in a drug-antibody ratio (DAR) of 2.0. The reliable performance ensures quantitative conjugation without affecting immunoreactivity.
Join us as Hanna Toftevall and Andreas Nägeli explore the technology and describe its functionality and versatility in applications from kit to clinic.
Key Learning Objectives
- Understand how GlyCLICK can be used from early-stage R&D through to clinical applications
- Benefits of site-specific conjugation for ADCs
- Generation of homogenous conjugates with defined and consistent DAR
Related Products
Related Applications
Site-specific ADC generation with defined DAR, preserving antigen binding and delivering potent, controlled cytotoxicity in target cells.
